Is Matrix Metalloproteinase-9 Associated with Post-Stroke Cognitive Impairment or Dementia?

被引:7
|
作者
Zhao, Jianhua [1 ]
Yang, Fangli [1 ]
Peng, Xue [2 ]
Li, Qing [1 ]
Wang, Fan [1 ]
Xu, Zhixiu [1 ]
Cai, Ruiyan [1 ]
Ji, Danxia [3 ]
Zhang, Jian [4 ]
Wang, Minghua [1 ]
Li, Qiong [1 ]
Ji, Sibei [1 ]
Li, Shaomin [5 ]
机构
[1] Xinxiang Med Univ, Affiliated Hosp 1, Henan Joint Int Res Lab Neurorestoratol Senile De, Henan Key Lab Neurorestoratol,Dept Neurol, Xinxiang 453100, Henan, Peoples R China
[2] Jianghan Univ, Hosp Wuhan 6, Dept Neurol, Affiliated Hosp, Wuhan 430015, Hubei, Peoples R China
[3] Xinxiang Med Univ, Dept Med Record Management, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[4] Xinxiang Med Univ, Dept Imaging, Affiliated Hosp 1, Xinxiang 453100, Henan, Peoples R China
[5] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA
关键词
ischemic stroke; post-stroke cognitive impairment or dementia (PSCID); matrix metalloprotenase 9; genetic polymorphism; cognitive function; METALLOPROTEINASE GENE POLYMORPHISMS; MATRIX METALLOPROTEINASES; HARMONIZATION STANDARDS; CEREBROSPINAL-FLUID; BRAIN; STROKE; DISEASE; INFLAMMATION; DYSFUNCTION; DISORDERS;
D O I
10.31083/j.jin2106160
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Matrix metalloproteinase-9 (MMP-9) is a significant protease required for synaptic plasticity, learning, and memory. Yet, the role of MMP-9 in the occurrence and development of cognitive decline after ischemic stroke is not fully understood. In this study, we used clinical data experiments to further investigate whether MMP-9 and genetic polymorphism are associated with poststroke cognitive impairment or dementia (PSCID). Materials and Methods: A total of 148 patients with PSCID confirmed by the Montreal Cognitive Assessment (MoCA) 3 months after onset (PSCID group) were included in the study. The MMP-9 rs3918242 polymorphisms were analyzed using polymerase chain reaction coupled with restriction fragment length polymorphism, and the serum level of MMP-9 was measured using enzyme-linked immunosorbent assay (ELISA). The same manipulations have been done on 169 ischemic stroke patients without cognitive impairment (NCI group) and 150 normal controls (NC group). Results: The expression level of serum MMP-9 in the PSCID group and NCI group was higher compared to the NC group, and the levels in the PSCID group were higher than that in the NCI group (all p < 0.05). Diabetes mellitus, hyperhomocysteinemia, and increased serum MMP-9 levels were the main risk factors of cognitive impairment after ischemic stroke. The serum level of MMP-9 was negatively correlated with the MoCA score, including visual-spatial executive, naming, attention, language, and delayed recall. Genetic polymorphism showed that TC genotype with MMP-9 rs3918242 and CC genotype were associated with a significantly increased risk of PSCID; moreover, the TC genotype significantly increased the risk of cognitive impairment. In the TCCC genotype of MMP-9 rs3918242, diabetes mellitus and hyperhomocysteinemia were associated with the increased risk of PSCID; also, hyperhomocysteinemia could increase the risk of cognitive impairment. Conclusions: MMP-9 level and MMP-9 rs3918242 polymorphism have an important role in the occurrence and development of post-stroke cognitive impairment or dementia (PSCID).
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Post-stroke cognitive impairment at 3 months
    Sundar, Uma
    Adwani, Sikandar
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2010, 13 (01) : 42 - 46
  • [22] Location of infarcts and post-stroke cognitive impairment
    Pantoni, Leonardo
    Salvadori, Emilia
    LANCET NEUROLOGY, 2021, 20 (06): : 413 - 414
  • [23] Early biomarkers for post-stroke cognitive impairment
    Lai Qian
    Lidong Ding
    Liqun Cheng
    Xiaolei Zhu
    Hui Zhao
    Jiali Jin
    Dening Guan
    Bing Zhang
    Xuemei Chen
    Yun Xu
    Journal of Neurology, 2012, 259 : 2111 - 2118
  • [24] Prevalence of cognitive impairment post-stroke by domain
    Middleton, L. E.
    Lam, B.
    Fahmi, H.
    Mcllroy, W.
    Turner, G.
    STROKE, 2011, 42 (11) : E615 - E615
  • [25] Early biomarkers for post-stroke cognitive impairment
    Qian, Lai
    Ding, Lidong
    Cheng, Liqun
    Zhu, Xiaolei
    Zhao, Hui
    Jin, Jiali
    Guan, Dening
    Zhang, Bing
    Chen, Xuemei
    Xu, Yun
    JOURNAL OF NEUROLOGY, 2012, 259 (10) : 2111 - 2118
  • [26] Frequency and risk factors associated with post-stroke dementia-an observational study on stroke patients without premorbid cognitive impairment
    Johnen, A.
    Raethe, S.
    Lohmann, H.
    Philipp, K.
    Minnerup, J.
    Wiendl, H.
    Meuth, S. G.
    Duning, T.
    NERVENARZT, 2020, 91 (02): : 131 - 140
  • [27] Prevalence of post-stroke cognitive impairment and associated risk factors in Chinese stroke survivors
    Chau, Janita Pak Chun
    Lo, Suzanne Hoi Shan
    Zhao, Jie
    Choi, Kai Chow
    Butt, Laveeza
    Lau, Alexander Yuk Lun
    Mok, Vincent Chung Tong
    Kwok, Zoe Ching Man
    Thompson, David R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [28] Impact of Post-Stroke Cognitive Impairment with No Dementia on Health-Related Quality of Life
    Park, Jung Hyun
    Kim, Beom Joon
    Bae, Hee-Joon
    Lee, Jisung
    Lee, Juneyoung
    Han, Moon-Ku
    Yoon, Kyung O.
    Park, Seong Ho
    Kang, Yeonwook
    Yu, Kyung-Ho
    Lee, Byung-Chul
    JOURNAL OF STROKE, 2013, 15 (01) : 49 - 56
  • [29] Intravenous Glyburide Treatment is Associated with Reduced Matrix Metalloproteinase-9 in Human Acute Stroke
    Pham, Ly
    O'Connor, Sydney
    Yarbrough, Karen
    Jacobson, Sven
    Stern, Barney J.
    Sheth, Kevin N.
    Kimberly, W. Taylor
    STROKE, 2013, 44 (02)
  • [30] Neuropsychological features in post-stroke cognitive impairment with no dementia patients with different tongue conditions
    Ma, J.
    Yang, P.
    Zhang, Y.
    Guo, Q.
    Zhou, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 842 - 842